Dr. Coyle Named Chief Scientific Advisor
July 05, 2022
Media - Eat This Not That
Dr. Tsai was quoted in the article “I’m a Virus Expert and It’s Still Dangerous to Go Here”
May 27, 2022
Media - Eat This Not That
Online article contributed by Dr. Tsai: “Virus Expert Says “Be Ready for This to Happen Next” — A new big wave of infection is coming to the U.S.”
SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® completed US Phase 2 clinical trial in June 2022 (click here for trial information). The Phase 3 study is expected to be launched in late 2022 as a global multi-center clinical trial. First-in-human study for Airnecflu® is expected to launch in the second half of 2022.
Pentarlandir for COVID-19 (Oral Antiviral)
Phase 2
Airneclfu for COVID-19 (Inhaler)
Phase 1
NaBen for Adult Schizophrenia
Phase 2/3
ClozaBen for Refractory Schizophrenia
Phase 2/3
NaBen for Adolescent Schizophrenia
Phase 2/3
Synapsinae for Depression and Suicidality
Phase 3
Synxyrin for Treatment Resistant Depression
Phase 2
SNB01
COVID-19
Antiviral
Antiviral
SND13
Adult
Schizophrenia
Schizophrenia
SND12
Refractory Schizophrenia
SND11
Adolescent Schizophrenia